---
title: "BIXT.US (BIXT.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/BIXT.US/news.md"
symbol: "BIXT.US"
name: "BIXT.US"
parent: "https://longbridge.com/zh-HK/quote/BIXT.US.md"
datetime: "2026-03-16T23:42:24.727Z"
locales:
  - [en](https://longbridge.com/en/quote/BIXT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BIXT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BIXT.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/BIXT.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/BIXT.US/news.md)


# BIXT.US (BIXT.US) — 相關新聞

### [Bioxytran Reports Positive Dose Optimization Results, Advances ProLectin-M Toward Phase 3 Trial](https://longbridge.com/zh-HK/news/277891827.md)
*2026-03-05T07:00:43.000Z*
> Bioxytran, Inc. (BIXT) reported positive results for its antiviral candidate ProLectin-M, confirming a 16,800 mg/day dos

### [Bioxytran sees positive dose optimization, moves to Phase 3 trial for ProLectin-M with 408 patients, targeting viral infected outpatients.](https://longbridge.com/zh-HK/news/277831578.md)
*2026-03-04T20:42:46.000Z*
> A company has begun regulatory discussions with the Central Drugs Standard Control Organization (CDSCO). They are planni

### [Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M | BIXT Stock News](https://longbridge.com/zh-HK/news/277829903.md)
*2026-03-04T12:40:00.000Z*
> Bioxytran, Inc. (OTCQB: BIXT) announced positive results for its antiviral candidate ProLectin-M, confirming a 16,800 mg

### [Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19  | BIXT Stock News](https://longbridge.com/zh-HK/news/277497967.md)
*2026-03-02T08:40:00.000Z*
> Bioxytran, Inc. (OTCQB:BIXT) announced positive results from a Phase 1b/2a clinical study of ProLectin-M, an oral antivi

### [BioNxt Announces Closing of Shares for Debt Settlement](https://longbridge.com/zh-HK/news/277117392.md)
*2026-02-27T00:00:00.000Z*
> BioNxt Solutions Inc. has closed a debt settlement by issuing 6,008,883 common shares at $0.45 each to settle $2,704,000

### [Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement](https://longbridge.com/zh-HK/news/276763986.md)
*2026-02-24T16:08:09.000Z*
> Bioxytran, Inc. has entered a commercial Distribution Agreement with Khoury Medical LTD for the A-SUQAR dietary suppleme

### [Bioxytran reports rapid viral clearance in phase 2 trial](https://longbridge.com/zh-HK/news/275621004.md)
*2026-02-11T14:24:07.000Z*
> Bioxytran has announced positive results from its phase 2 trial of ProLectin-M, showing rapid viral clearance in patient